Financial Performance - The company's revenue for Q1 2023 was CNY 473,030,518.35, representing a 27.63% increase compared to CNY 370,629,245.42 in the same period last year[5] - Net profit attributable to shareholders for Q1 2023 was CNY 138,474,386.29, a significant increase of 171.11% from CNY 51,076,948.02 in the previous year[5] - The net profit after deducting non-recurring gains and losses was CNY 125,533,224.91, up 157.67% from CNY 48,718,416.30 year-on-year[5] - The basic earnings per share for Q1 2023 was CNY 0.3236, an increase of 171.02% compared to CNY 0.1194 in the same period last year[10] - Total operating revenue for Q1 2023 reached ¥473,030,518.35, an increase of 27.7% compared to ¥370,629,245.42 in Q1 2022[19] - Operating profit for Q1 2023 was ¥149,428,037.24, up 165.7% from ¥56,213,208.39 in the same period last year[19] - Net profit attributable to the parent company for Q1 2023 was ¥138,474,386.29, a significant increase from ¥51,076,948.02 in Q1 2022, representing a growth of 171.5%[20] - Basic earnings per share for Q1 2023 were ¥0.3236, compared to ¥0.1194 in Q1 2022, reflecting a 171.5% increase[20] Assets and Liabilities - Total assets at the end of Q1 2023 were CNY 3,692,458,938.45, reflecting a 4.18% increase from CNY 3,544,216,145.59 at the end of the previous year[5] - The total current assets amounted to ¥2,633,566,082.40, up from ¥2,514,310,007.04, indicating an increase of about 4.7%[15] - The total assets of the company reached ¥3,692,458,938.45, compared to ¥3,544,216,145.59 at the beginning of the year, reflecting a growth of approximately 4.2%[16] - The total liabilities decreased to ¥762,787,304.45 from ¥804,413,526.41, a reduction of approximately 5.2%[17] - Total equity attributable to shareholders increased to ¥2,929,671,634.00 from ¥2,739,802,619.18, marking a growth of 6.9%[17] Cash Flow - The company's cash and cash equivalents at the end of Q1 2023 amounted to CNY 148,591,670.00, which is a 50.16% increase from CNY 98,957,000.00 year-on-year[10] - The net cash flow from operating activities for Q1 2023 was CNY 48,269,069.80, a decrease of 7.21% compared to CNY 52,021,509.15 in the same period last year[5] - Cash generated from operating activities was ¥509,891,004.68, compared to ¥459,218,493.82 in the previous year, indicating an increase of 11.1%[21] - The net cash flow from operating activities for Q1 2023 was ¥48,269,069.80, a decrease of 1.44% compared to ¥52,021,509.15 in Q1 2022[22] - The total cash and cash equivalents at the end of Q1 2023 reached ¥1,485,916,653.31, up from ¥989,579,920.30 at the end of Q1 2022, representing a significant increase of 50.3%[23] Expenses - The company experienced a 44.05% increase in selling expenses, totaling CNY 10,568,180.00, primarily due to increased human resources and travel costs[9] - The company’s financial expenses decreased by 464.05% to -CNY 730,460.00, mainly due to increased interest income[9] - Research and development expenses for Q1 2023 were ¥80,009,904.74, up from ¥75,702,238.74 in Q1 2022, reflecting a growth of 5.4%[19] - Sales expenses increased to ¥105,681,831.55 from ¥73,365,183.75, a rise of 43.9% year-over-year[19] - Cash paid for purchasing goods and services was ¥194,127,831.33, an increase of 22.47% compared to ¥158,565,395.48 in Q1 2022[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 13,518[11] - The largest shareholder, Chen Zhiqiang, holds 22.37% of the shares, totaling 95,725,200 shares, with 11,500,000 shares pledged[12] Other Information - The company reported a total of CNY 12,941,161.38 in non-recurring gains and losses for Q1 2023[6] - The company did not conduct an audit for the Q1 2023 report[24]

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2022, representing a year-on-year increase of 15% compared to 2021[13]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the year, representing a growth of 20% compared to the previous year[76]. - The company achieved a total revenue of 1,762.649 million yuan in 2022, representing a year-on-year growth of 22.02%[49]. - The revenue from the ultrasound product line was ¥1,079,527,925.32, accounting for 61.24% of total revenue, with a growth of 14.14% from ¥945,800,908.14 in 2021[56]. - The revenue from endoscopes and related treatment instruments increased by 42.98% to ¥611,598,329.82, representing 34.70% of total revenue[56]. - The company reported a net profit of 300 million RMB for 2022, reflecting a growth of 20% compared to the previous year[13]. - Net profit attributable to shareholders for 2022 was ¥369,811,713.74, a 49.57% increase from ¥247,244,612.13 in 2021[19]. - The gross profit margin for 2022 was 45%, which is a slight improvement from 43% in the previous year[13]. - The company reported a gross margin of 60%, maintaining a stable margin despite rising raw material costs[76]. - The company reported a significant increase in trading financial assets to CNY 419.45 million, accounting for 11.83% of total assets, due to increased purchases of financial products[92]. Research and Development - The company's R&D expenses accounted for approximately 20% of its operating revenue in recent years, indicating a strong commitment to innovation despite inherent risks in product development[2]. - The company invested in R&D with expenditures of CNY 237.42 million, CNY 263.06 million, and CNY 328.96 million for the years 2020, 2021, and 2022, respectively, representing 20.41%, 18.21%, and 18.66% of total revenue[41]. - The company has a dedicated R&D team of 631 personnel, accounting for 27.04% of total employees, ensuring a strong focus on product development[43]. - The company has developed advanced ultrasound technologies, including high-frequency probe technology and AI image recognition, positioning itself as a leader in the ultrasound field[40]. - The company launched the world's first AI-based dynamic image technology for prenatal ultrasound screening, enhancing efficiency in obstetric examinations[30]. - The company is focusing on improving customer service and support processes, which has led to increased customer satisfaction and repeat purchases[48]. - The company is committed to ongoing research and development to maintain its competitive edge in the medical technology sector[79]. Market Expansion - The company is expanding its market presence in Europe, with plans to establish a new distribution center in Germany by mid-2023[13]. - The company is actively pursuing market expansion and product innovation to enhance its competitive position in the medical device sector[67]. - The company is expanding its market presence in Southeast Asia, with plans to enter three new countries by the end of 2023[112]. - The company has established a global marketing network covering nearly 130 countries and regions, enhancing its brand promotion and distributor training capabilities[43]. - The company is committed to localizing its operations in developed markets while refining its approach in developing markets, resulting in rapid business growth in regions like the US, Germany, and India[53]. Product Development - The company plans to launch three new ultrasound products in 2023, aiming to capture a larger market share in the medical imaging sector[13]. - The company has launched new products, including the P12 Elite and P20 Elite series ultrasound diagnostic systems, which were registered on September 15 and September 13, 2022, respectively[84]. - The company has introduced several new products in the endoscope field, including ultra-thin electronic gastroscopes and electronic colonoscopes, significantly enriching its product offerings and supporting market penetration[50]. - The company has launched the ProPet series of veterinary ultrasound products in 2022, expanding its market reach in ultrasound applications[35]. - The company has developed a unique competitive advantage in the hard endoscope field by integrating hard endoscopes with ultrasound systems[32]. Regulatory Compliance - The company is subject to significant regulatory risks due to the medical device industry's heavy government oversight, which could impact pricing and market dynamics[5]. - The company has received multiple certifications, including NMPA, FDA, and CE, ensuring compliance with international quality standards for its medical devices[44]. - The company has maintained compliance with internal control standards, ensuring the accuracy and completeness of financial reporting[160]. - The company has not reported any violations regarding external guarantees during the reporting period[171]. Corporate Governance - The board of directors held five meetings during the reporting period to ensure effective governance and decision-making[113]. - The company has established a comprehensive performance evaluation and incentive mechanism for its directors, supervisors, and senior management, ensuring competitive compensation[119]. - The company has a robust governance structure with independent directors who bring diverse expertise, including legal and engineering backgrounds[131]. - The company is committed to protecting the legal rights of shareholders through effective governance practices[142]. Financial Management - The company reported a total cash outflow from operating activities of CNY 1,663,498,449.80, which is a 16.82% increase from CNY 1,423,986,369.23 in the previous year[88]. - The net cash flow from operating activities reached ¥473,255,552.95, up 56.20% from ¥302,989,915.92 in 2021[19]. - The total amount of funds raised in 2021 was CNY 769,055,967.35 after deducting issuance costs, with no funds utilized as of the reporting period[100]. - The company has committed to invest CNY 24,705.43 million in the development of color ultrasound and endoscope products, with a cumulative investment of CNY 24,321.31 million, achieving 100.46% of the planned progress[102]. Strategic Initiatives - The company plans to implement a new marketing strategy aimed at increasing brand awareness, with a budget allocation of 100 million RMB for 2023[112]. - The company is exploring potential acquisitions to enhance its product portfolio, focusing on companies specializing in diagnostic imaging technologies[76]. - The company completed a strategic acquisition of a smaller biotech firm for 500 million RMB to enhance its product portfolio[112]. - The company has implemented a training program focused on team capability development, emphasizing a "people-oriented, technology innovation" philosophy[150].

关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳开立生物医疗科技股份有限公司（以下简称"公司"）定于 2023 年 4 月 18 日（星期二）下午 15:00-17:00 在全景网举办 2022 年度网上业绩说明会， 本次年度业绩说明会将采用网络远程的方式举行，投资者可登录全景网"投资 者关系互动平台"（http://ir.p5w.net）参与互动交流。 出席本次年度网上业绩说明会的人员包括：公司董事长陈志强先生、董事 会秘书李浩先生、财务总监罗曰佐先生、独立董事华小宁先生、保荐代表人郭 小元先生。 证券代码：300633 证券简称：开立医疗 公告编号：2023-015 深圳开立生物医疗科技股份有限公司 为做好中小投资者保护工作，增进投资者对公司的了解和认同，以提升公 司治理水平和企业整体价值，现就公司 2022 年度网上业绩说明会提前向投资者 征集相关问题，投资者可于 2023 年 4 月 17 日（星期一）17:00 前将有关问题通 过电子邮件的形式发送至公司投资者关系互动邮箱：ir@sonoscape.n ...